A primitive CD34+ subpopulation of a human erythroleukemia multidrug-resistance cell lineage (K562), possesses greater resistance to imatinib than the majority CD34- population sensitive to the elevated ROS levels by the combination of simvastatin and imatinib [23]. This evidence concerns the gene CD34 and erythroleukemia.